Noticed an interesting pattern in ARK's portfolio movements at the end of February. Cathie Wood is clearly looking for opportunities where the market panics. Remember CoreWeave? Cloud infrastructure for AI dropped 19% after mixed quarterly results, but instead of avoiding the stock, ARK Invest turned around and bought approximately $19.4 million worth. This is a classic move — when everyone is selling in panic, the fund sees potential. CoreWeave showed strong revenue, just expenses were higher than expected. For a company operating in the AI computing sector, this doesn’t look like a red flag.

By the way, Wall Street consensus on CoreWeave is quite optimistic — a target price of $114 suggests a potential upside of 43.5% from current levels. Eleven buy ratings and eight hold ratings.

The largest purchase of the day was Kratos Defense & Security Solutions — over 252,000 shares worth $23.2 million. The company specializes in drones and autonomous defense systems, aligning with ARK’s long-term themes of robotics and automation. This direction clearly interests Cathie Wood.

But there was more. ARK sold positions in Teradyne — a manufacturer of semiconductor testers. This continues a trend that started a week earlier. They also reduced Rocket Lab by about $3.4 million, even though the company just reported better-than-expected results. However, the launch of the new Neutron rocket was postponed to late 2026, which clearly cooled the market.

In biotech, Cathie Wood bought Generate Biomedicines for $7.4 million but simultaneously sold Ionis Pharmaceuticals. There were also small moves — selling Roku, reducing Guardant Health, and PagerDuty. In total, the two largest deals of the day — CoreWeave and Kratos — amounted to over $42 million. It’s evident that the fund is actively rebalancing, looking for new entry points into AI and defense technologies, while carefully exiting positions that have already appreciated in value.